1134 - A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients with Unresectable and Borderline Resectable Pancreatic Cancer
Presenter(s)
U. Amit Sr1,2, J. M. Metz2, J. P. Plastaras3, U. Teitelbaum4, R. Gheewala2, N. Damjanov5, C. Vollmer6, C. Schneider7, K. Lee6, M. O’Hara7, E. Carpenter7, T. B. Karasic8, A. A. Konski2, and E. Ben-Josef2; 1Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel, 2Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 3Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 4Department of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA, 5Department of Medical Oncology, University of Pennsylvania, Philadelphia, PA, 6Department of Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Philadelphia, PA, 7Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 8Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
Purpose/Objective(s): This Phase I dual dose-escalation study aimed to evaluate the safety, feasibility, and toxicity profile of combining dose-escalated radiation therapy with high-dose nab-paclitaxel in patients with unresectable or borderline resectable pancreatic cancer. The primary objective was to determine the maximum tolerated radiation dose for the combination.
Materials/Methods: Twenty-one evaluable patients were enrolled and allocated three radiation dose levels, 55 Gy, 57.5 Gy, and 60 Gy, administered over five weeks in 25 fractions. Concurrent nab-paclitaxel was given weekly at a dose of 125 mg/m². Radiation dose escalation was guided by a time-to-event continual reassessment method. Toxicities were monitored and classified according to CTCAE v4.0, with dose-limiting toxicities (DLT) defined as grade 3 or higher gastrointestinal events or substantial decline in performance status. Surgical resection was pursued in patients achieving sufficient tumor downstaging.
Results: Hematologic toxicities were the most common grade= 3 adverse events occurring in 76.2% of patients. Non-hematologic toxicities were less frequent (57.1%). Two grade 3 gastrointestinal DLT cases occurred at dose levels 57.5 Gy and 60 Gy. The maximum tolerated dose was determined to be 60 Gy with a probability of DLT of 0.155 at this dose. Surgical resection with negative margins (R0) was achieved in 33.3% of patients, including all borderline resectable cases and 22.2% of initially unresectable cases. The median overall survival and time to local progression from the start of radiation therapy were 22.3 months and 20.3 months, respectively.
Conclusion: This study demonstrates the feasibility and safety of combining dose-escalated radiation with high-dose nab-paclitaxel in locally advanced pancreatic cancer. The regimen is associated with manageable toxicity and promising local control and survival. These findings support further evaluation in larger trials to assess its impact on clinical outcomes.